Affluent Medical SA — Cyborg Score 4/10

Strategic Profile

Founded by Truffle Capital, Affluent Medical aims to become a global benchmark player in the field of urology and interventional cardiology. The company recently became Carvolix and announced the finalisation of acquisitions of Caranx Medical and Artedrone, signaling a shift toward strategic consolidation to build comprehensive treatment portfolios.

Cyborg Score Rationale

The company has negative EBITDA of -13.52M EUR with EBITDA margin of -323.58%. Net income for the last half-year was -9.37M EUR, worsening from -5.37M EUR in the previous report. While facing profitability challenges, 3 analysts recommend buying the stock with a Strong Buy rating.

Top Insights

• The company's three medical devices are currently in the clinical phase with CE marking and launches expected soon in target markets
• Recent acquisitions of Caranx Medical and Artedrone expand treatment capabilities and represent major strategic pivot
• 3 analysts set average 12-month price target at EUR3.6 with high estimate of EUR4.6 (150%+ upside)
• As of Nov 2025, the company has 77 employees, indicating lean operational structure typical of clinical-stage medtech

Named Competitors

• Sapien Transcatheter Heart Valve — Market leader in transcatheter heart valve replacement
• MitraClip — Mitral valve repair device and market standard
• Entellus Medical Portfolio — Minimally invasive surgical solutions

Recent Developments

• (March 2025) Key appointments announced for Medical and Clinical affairs leadership
• (Recent) Company transitioned to Carvolix brand and completed acquisitions of Caranx Medical and Artedrone
• (2021) IPO on Euronext Paris raised €25 million with market cap over €156 million

Open the full interactive Affluent Medical SA report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.